SuperGen, Inc. (NASDAQ:SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that James S.J. Manuso, Ph.D., president and chief executive officer, will present at BioEquity Europe 2011 on Monday and Tuesday, May 23rd and 24th in Paris.

SuperGen's corporate presentation will take place on May 23 at 11:00 a.m. CEST. In addition, Dr. Manuso will participate in a panel discussion titled, “Strategy: Squaring the Circle” about building companies to study disease biology based on platform technology, on May 24 at 1:45 p.m. CEST. More information on the panel can be found at http://www.biocentury.com/Conferences.

About SuperGen

SuperGen is a pharmaceutical company dedicated to discovery and development of novel cancer therapeutics in epigenetic and cell signaling modulation. The Company develops products through biochemical and clinical proof of concept to partner for further development and commercialization. On April 6, 2011, SuperGen entered into a definitive merger agreement to acquire Astex Therapeutics Limited, a UK based biotechnology company. The transaction is subject to customary regulatory, legal and shareholder approvals. For more information about SuperGen, please visit http://www.supergen.com.

Supergen, Inc. (MM) (NASDAQ:SUPG)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024 Click aqui para mais gráficos Supergen, Inc. (MM).
Supergen, Inc. (MM) (NASDAQ:SUPG)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024 Click aqui para mais gráficos Supergen, Inc. (MM).